Daré Bioscience Highlights Commercial Launch Readiness for DARE to PLAY™ Sildenafil Cream; November 17th Webinar to Feature Leading Clinicians Discussing Clinical Data and Potential Impact in Women’s Sexual Health

Core Insights - Daré Bioscience is hosting a webinar on November 17, 2025, to discuss its innovative product DARE to PLAY™, a topical sildenafil cream designed specifically for women [1][2] - DARE to PLAY™ is the first evidence-backed sildenafil cream for women, showing increased genital blood flow within 10 to 15 minutes of application and improvements in arousal sensations [2][3] - The product is expected to be commercially available through a 503B outsourcing facility by the end of 2025, marking a significant advancement in women's sexual health solutions [2][3] Company Overview - Daré Bioscience focuses on addressing gaps in women's health through science-based solutions, with a commitment to rigorous clinical research and development [4][5] - The company aims to provide credible, evidence-based therapies for various women's health issues, including sexual health, menopause, and fertility [4][5] - Daré is a female-led organization recognized for its contributions to innovation and advocacy in women's health, with leadership acknowledged in industry publications [6] Product Details - DARE to PLAY™ is a unique formulation that enhances genital blood flow and arousal response, supported by FDA-reviewed clinical data [2][3] - The product's anticipated launch will be the first time a topical sildenafil formulation manufactured under cGMP requirements is available to healthcare providers [2][3] - The webinar will feature expert clinicians discussing the product's benefits and clinical data, providing an opportunity for participants to join a product alert list [3]